Zobrazeno 61 - 70
of 1 117
pro vyhledávání: ''
Autor:
Helga B. Salvesen, Katrien Berns, James D. Brenton, Joseph J Caumanns, Michael J. Birrer, Tushar Tomar, Els Van Nieuwenhuysen, Rudolf S N Fehrmann, Ignace Vergote, Jolanta Kupryjanczyk, Evelien W. Duiker, Roelof J.C. Kluin, René Bernards, An K.L. Reyners, Gert Jan Meersma, Steven de Jong, Beata Spiewankiewicz, Elena Ioana Braicu, G. Bea A. Wisman, Annemiek M.C. Gennissen, E. Marielle Hijmans, Hiroaki Itamochi, Ate G.J. van der Zee, Harry G. Klip, Desiree Weening, Lorenza Mittempergher
Publikováno v:
Clinical Cancer Research, 24(16), 3928-3940. AMER ASSOC CANCER RESEARCH
Purpose: Advanced-stage ovarian clear cell carcinoma (OCCC) is unresponsive to conventional platinum-based chemotherapy. Frequent alterations in OCCC include deleterious mutations in the tumor suppressor ARID1A and activating mutations in the PI3K su
Autor:
Ka Fai To, Guang-Yu Lian, Xiao-Ru Huang, Qing-Ming Wang, Jinghong Li, Hui-Yao Lan, Chunjie Li, Patrick Ming-Kuen Tang
Publikováno v:
Cancer Immunology Research. 6:965-977
Natural killer (NK) cells, early effectors in anticancer immunity, are paralyzed by TGFβ1, an immunosuppressive cytokine produced by cancer cells. Development and activity of NK cells are largely inhibited in the Smad3-dependent tumor microenvironme
Autor:
Mark X. Sliwkowski, Jun Guo, Lisa Crocker, Jennifer A. Lacap, Gail Lewis Phillips, Ben-Quan Shen, Daniela Bumbaca Yadav, Guangmin Li
Publikováno v:
Molecular Cancer Therapeutics. 17:1441-1453
The receptor tyrosine kinase HER2 is overexpressed in approximately 20% of breast cancer, and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla, T-DM1), an antibody–drug conjugate that is comprised of trastuzumab
Autor:
Siwen Kang, Jianying Zhang, Elshafa H. Ahmed, Michael A. Caligiuri, Erin N. Glankler, Don M. Benson, Youssef Youssef, Emma R. Barrett, Wing Keung Chan, Jianhua Yu, Luxi Chen, Aman Prasad, Alex M. Carter
Publikováno v:
Cancer Immunology Research. 6:776-787
Multiple myeloma (MM) is an incurable hematologic malignancy of plasma cells, with an estimated 30,000 new cases diagnosed each year in the United States, signifying the need for new therapeutic approaches. We hypothesized that targeting MM using a b
Autor:
Isaac K. Nardi, Dan J. Raz, Lu Yang, Jinhui Wang, Jami Wang, Rajendra P. Pangeni, Xinwei Yun, Melissa Bonner, Ming Gao, Keqiang Zhang, Jun Wu
Publikováno v:
Molecular Cancer Research. 16:1161-1171
Loss of monoubiquitination of histone H2B (H2Bub1) was found to be associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. This study investigated the association and impact of the ubiquitin-specific peptidase 22 (USP22),
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Autor:
Irene M. Ghobrial, Natalie Bezman, Michele Moschetta, Antonio Sacco, Aldo M. Roccaro, Yu-Tzu Tai, Daisy Huynh, Siobhan Glavey, Yuji Mishima, Alexandre Detappe, Jamil Azzi, Jennifer L. Guerriero, Ahmed T. Kurdi, Amy Jhatakia, Chia Jen Liu, Michael Robbins, Salomon Manier
Publikováno v:
Molecular Cancer Therapeutics. 17:1454-1463
Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effe
Autor:
Yu Qiao, Jingxuan Yang, Shanshan Sun, Chuanqiang Wu, Yu Wang, Minghui Zhao, Xudong Wang, Xuan Zhou, Mingyang Liu, Min Li, Feng Yu, Lun Zhang, Zhaoqing Li, Chao Zhang, Yu Ren, Lingping Kong, Yuqing Zhang, Chao Jing, Xiaofeng Yao, Yansheng Wu, Wenyu Guo
Publikováno v:
Clinical Cancer Research. 24:2665-2677
Purpose: PI3K and STAT3 are frequently activated in cancer progression. However, little is known about the underlying mechanisms by which PI3K and STAT3 regulate head and neck squamous cell cancer (HNSCC) growth. The lncRNA HOX transcript antisense R
Autor:
Marina Kem, Sotirios Lakis, Maria Gomez-Caraballo, Roopika Menon, Peter Igo, Ruben Dries, Mari Mino-Kenudson, Reinhard Büttner, Shyamala Maheswaran, Daniel A. Haber, Kwok-Kin Wong, David T. Myers, Camilla L. Christensen, Joseph A. LiCausi, Sarah Phat, Tilak K. Sundaresan, Jun Zhong, Benjamin J. Drapkin, Lecia V. Sequist, Stefan A. Haas, Nicholas J. Dyson, Anna F. Farago, Julie George, Kandarp Jani, Aaron N. Hata, Nima Abedpour, Mehmet Toner, Alice T. Shaw, Martin Peifer, Rebecca S. Heist, Roman K. Thomas, Mehlika Hazar-Rethinam, Roxana Azimi
Publikováno v:
Cancer Discovery
Small cell lung cancer (SCLC) patient-derived xenografts (PDX) can be generated from biopsies or circulating tumor cells (CTC), though scarcity of tissue and low efficiency of tumor growth have previously limited these approaches. Applying an establi
Autor:
Guo Hua, Baicai Yang, Ruibing Chen, Wen Wei, Ning Zhang, Hao Zhuang, Yun Liu, Yuan Li, Xinran Zhang, Yongmei Li
Publikováno v:
Cancer Research. 78:2219-2232
Invasion and intrahepatic metastasis are major factors of poor prognosis in patients with hepatocellular carcinoma (HCC). In this study, we show that increased Src homolog and collagen homolog 3 (Shc3) expression in malignant HCC cell lines associate
Autor:
Chang Liu, Xin Du, Yangqiu Li, Juan Li, Jingxuan Pan, Jingfeng Zhou, Danian Nie, Yanli Jin, Yuhong Lu
Publikováno v:
Cancer Research. 78:1522-1536
Imatinib revolutionized the treatment of chronic myeloid leukemia (CML), but drug resistance and disease recurrence remain a challenge. In this study, we suggest a novel strategy based on blocking protein neddylation to address BCR-ABL point mutation